Patient Treatment Characteristics (n = 24 Patients)
| Characteristic | Data |
|---|---|
| Median time from PSMA PET/CT to metastasis-directed radiotherapy (mo) | 1.4 (IQR, 0.9–2.8) |
| Treated sites (n) | |
| 1 | 11 (45.8%) |
| 2 | 10 (41.7%) |
| 3 | 3 (12.5%) |
| Concurrent systemic therapy (n) | |
| ADT | 4 (16.7%) |
| ADT + sipuleucel-T | 3 (12.5%) |
| ADT + ARPI | 16 (66.7%) |
| ADT + ARPI + sipuleucel-T | 1 (4.2%) |
| Change in systemic therapy (n) | |
| Continued preexisting systemic therapy | 17 (70.8%) |
| Started new systemic therapy | 7 (29.2%) |